(Reuters) - By Bill Berkrot
NEW YORK, June 19 - U.S. health regulators have granted priority review for Bristol-Myers Squibb Co.'s experimental breast cancer drug ixabepilone, and an approval decision on the medicine could come by late October, the company said on Tuesday.
Read more at Reuters.com Government Filings News
NEW YORK, June 19 - U.S. health regulators have granted priority review for Bristol-Myers Squibb Co.'s experimental breast cancer drug ixabepilone, and an approval decision on the medicine could come by late October, the company said on Tuesday.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment